The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

Stefano Luminari, I. Biasoli, A. Versari, S. Rattotti, C. Bottelli, C. Rusconi, F. Merli, M. Spina, A. J M Ferreri, P. L. Zinzani, A. Gallamini, A. Franceschetto, C. Boccomini, S. Franceschetti, F. Salvi, F. D. Raimondo, A. M. Carella, Q. Micol, M. Balzarotti, P. MustoM. Federico

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: [18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods: In a subset analysis of the FOLL05 trial (NCT00774826), we investigated the prognostic role of post-induction PET (PI-PET) scan. Patients were eligible to this study if they had a PI-PET scan carried out within 3 months from the end of induction immunochemotherapy. Progression-free survival (PFS) was the primary study end point. Results: A total of 202 patients were eligible and analysed for this study. The median age was 55 years (range 33-75). Overall, PI-PET was defined as positive in 49 (24%) patients. Conventional response assessment with CT scan was substantially modified by PET: 15% (22/145) of patients considered as having a complete response (CR) after CT were considered as having partial response (PR) after PI-PET and 53% (30/57) patients considered as having a PR after CT were considered as a CR after PI-PET. With a median follow-up of 34 months, the 3-year PFS was 66% and 35%, respectively, for patients with negative and positive PI-PET (P <0.001). At multivariate analysis, PI-PET (hazard ratio 2.57, 95% confidence interval 1.52-4.34, P <0.001) was independent of conventional response, FLIPI and treatment arm. Also, the prognostic role of PI-PET was maintained within each FLIPI risk group. Conclusions: In FL patients, PI-PET substantially modifies response assessment and is strongly predictive for the risk of progression. PET should be considered in further updates of response criteria.

Original languageEnglish
Article numbermdt562
Pages (from-to)442-447
Number of pages6
JournalAnnals of Oncology
Volume25
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Follicular Lymphoma
Positron-Emission Tomography
Disease-Free Survival
Fluorodeoxyglucose F18
Multivariate Analysis
Confidence Intervals

Keywords

  • FDG-PET
  • Follicular lymphoma
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma : A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). / Luminari, Stefano; Biasoli, I.; Versari, A.; Rattotti, S.; Bottelli, C.; Rusconi, C.; Merli, F.; Spina, M.; Ferreri, A. J M; Zinzani, P. L.; Gallamini, A.; Franceschetto, A.; Boccomini, C.; Franceschetti, S.; Salvi, F.; Raimondo, F. D.; Carella, A. M.; Micol, Q.; Balzarotti, M.; Musto, P.; Federico, M.

In: Annals of Oncology, Vol. 25, No. 2, mdt562, 2014, p. 442-447.

Research output: Contribution to journalArticle

Luminari, S, Biasoli, I, Versari, A, Rattotti, S, Bottelli, C, Rusconi, C, Merli, F, Spina, M, Ferreri, AJM, Zinzani, PL, Gallamini, A, Franceschetto, A, Boccomini, C, Franceschetti, S, Salvi, F, Raimondo, FD, Carella, AM, Micol, Q, Balzarotti, M, Musto, P & Federico, M 2014, 'The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)', Annals of Oncology, vol. 25, no. 2, mdt562, pp. 442-447. https://doi.org/10.1093/annonc/mdt562
Luminari, Stefano ; Biasoli, I. ; Versari, A. ; Rattotti, S. ; Bottelli, C. ; Rusconi, C. ; Merli, F. ; Spina, M. ; Ferreri, A. J M ; Zinzani, P. L. ; Gallamini, A. ; Franceschetto, A. ; Boccomini, C. ; Franceschetti, S. ; Salvi, F. ; Raimondo, F. D. ; Carella, A. M. ; Micol, Q. ; Balzarotti, M. ; Musto, P. ; Federico, M. / The prognostic role of post-induction FDG-PET in patients with follicular lymphoma : A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). In: Annals of Oncology. 2014 ; Vol. 25, No. 2. pp. 442-447.
@article{ec85c85bda8d452db96e1123d787891b,
title = "The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)",
abstract = "Background: [18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods: In a subset analysis of the FOLL05 trial (NCT00774826), we investigated the prognostic role of post-induction PET (PI-PET) scan. Patients were eligible to this study if they had a PI-PET scan carried out within 3 months from the end of induction immunochemotherapy. Progression-free survival (PFS) was the primary study end point. Results: A total of 202 patients were eligible and analysed for this study. The median age was 55 years (range 33-75). Overall, PI-PET was defined as positive in 49 (24{\%}) patients. Conventional response assessment with CT scan was substantially modified by PET: 15{\%} (22/145) of patients considered as having a complete response (CR) after CT were considered as having partial response (PR) after PI-PET and 53{\%} (30/57) patients considered as having a PR after CT were considered as a CR after PI-PET. With a median follow-up of 34 months, the 3-year PFS was 66{\%} and 35{\%}, respectively, for patients with negative and positive PI-PET (P <0.001). At multivariate analysis, PI-PET (hazard ratio 2.57, 95{\%} confidence interval 1.52-4.34, P <0.001) was independent of conventional response, FLIPI and treatment arm. Also, the prognostic role of PI-PET was maintained within each FLIPI risk group. Conclusions: In FL patients, PI-PET substantially modifies response assessment and is strongly predictive for the risk of progression. PET should be considered in further updates of response criteria.",
keywords = "FDG-PET, Follicular lymphoma, Prognosis",
author = "Stefano Luminari and I. Biasoli and A. Versari and S. Rattotti and C. Bottelli and C. Rusconi and F. Merli and M. Spina and Ferreri, {A. J M} and Zinzani, {P. L.} and A. Gallamini and A. Franceschetto and C. Boccomini and S. Franceschetti and F. Salvi and Raimondo, {F. D.} and Carella, {A. M.} and Q. Micol and M. Balzarotti and P. Musto and M. Federico",
year = "2014",
doi = "10.1093/annonc/mdt562",
language = "English",
volume = "25",
pages = "442--447",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - The prognostic role of post-induction FDG-PET in patients with follicular lymphoma

T2 - A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

AU - Luminari, Stefano

AU - Biasoli, I.

AU - Versari, A.

AU - Rattotti, S.

AU - Bottelli, C.

AU - Rusconi, C.

AU - Merli, F.

AU - Spina, M.

AU - Ferreri, A. J M

AU - Zinzani, P. L.

AU - Gallamini, A.

AU - Franceschetto, A.

AU - Boccomini, C.

AU - Franceschetti, S.

AU - Salvi, F.

AU - Raimondo, F. D.

AU - Carella, A. M.

AU - Micol, Q.

AU - Balzarotti, M.

AU - Musto, P.

AU - Federico, M.

PY - 2014

Y1 - 2014

N2 - Background: [18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods: In a subset analysis of the FOLL05 trial (NCT00774826), we investigated the prognostic role of post-induction PET (PI-PET) scan. Patients were eligible to this study if they had a PI-PET scan carried out within 3 months from the end of induction immunochemotherapy. Progression-free survival (PFS) was the primary study end point. Results: A total of 202 patients were eligible and analysed for this study. The median age was 55 years (range 33-75). Overall, PI-PET was defined as positive in 49 (24%) patients. Conventional response assessment with CT scan was substantially modified by PET: 15% (22/145) of patients considered as having a complete response (CR) after CT were considered as having partial response (PR) after PI-PET and 53% (30/57) patients considered as having a PR after CT were considered as a CR after PI-PET. With a median follow-up of 34 months, the 3-year PFS was 66% and 35%, respectively, for patients with negative and positive PI-PET (P <0.001). At multivariate analysis, PI-PET (hazard ratio 2.57, 95% confidence interval 1.52-4.34, P <0.001) was independent of conventional response, FLIPI and treatment arm. Also, the prognostic role of PI-PET was maintained within each FLIPI risk group. Conclusions: In FL patients, PI-PET substantially modifies response assessment and is strongly predictive for the risk of progression. PET should be considered in further updates of response criteria.

AB - Background: [18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods: In a subset analysis of the FOLL05 trial (NCT00774826), we investigated the prognostic role of post-induction PET (PI-PET) scan. Patients were eligible to this study if they had a PI-PET scan carried out within 3 months from the end of induction immunochemotherapy. Progression-free survival (PFS) was the primary study end point. Results: A total of 202 patients were eligible and analysed for this study. The median age was 55 years (range 33-75). Overall, PI-PET was defined as positive in 49 (24%) patients. Conventional response assessment with CT scan was substantially modified by PET: 15% (22/145) of patients considered as having a complete response (CR) after CT were considered as having partial response (PR) after PI-PET and 53% (30/57) patients considered as having a PR after CT were considered as a CR after PI-PET. With a median follow-up of 34 months, the 3-year PFS was 66% and 35%, respectively, for patients with negative and positive PI-PET (P <0.001). At multivariate analysis, PI-PET (hazard ratio 2.57, 95% confidence interval 1.52-4.34, P <0.001) was independent of conventional response, FLIPI and treatment arm. Also, the prognostic role of PI-PET was maintained within each FLIPI risk group. Conclusions: In FL patients, PI-PET substantially modifies response assessment and is strongly predictive for the risk of progression. PET should be considered in further updates of response criteria.

KW - FDG-PET

KW - Follicular lymphoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84893372842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893372842&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt562

DO - 10.1093/annonc/mdt562

M3 - Article

C2 - 24412823

AN - SCOPUS:84893372842

VL - 25

SP - 442

EP - 447

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

M1 - mdt562

ER -